Also it has a role in predicting colorectal cancers with worse prognosis and in identifying colorectal cancers lacking BRAF mutation that are more likely to respond to epidermal growth factor receptor inhibitor therapy [10, 11]. This evidence concerns the gene EGFR and colorectal cancer.